Compare Stocks: AKTX, IMMP, TCRX, and TIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$9.85 -7.9%	$9.61	$3.02 ▼ $49.60	$19.21M	1.41	317,286 shs	56,721 shs
IMMP Prima BioMed	$0.37 -4.1%	$0.40	$0.29 ▼ $3.53	$53.86M	2.25	5.76 million shs	106,460 shs
TCRX TScan Therapeutics	$0.73 -3.8%	$0.87	$0.72 ▼ $2.57	$49.15M	1.06	670,385 shs	218,070 shs
TIL Instil Bio	$7.70 +1.6%	$7.48	$5.67 ▼ $33.83	$52.21M	1.94	55,466 shs	504 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+36.31%	+36.13%	-20.33%	-64.80%
IMMP Prima BioMed	0.00%	-1.32%	-0.26%	-4.18%	-76.34%
TCRX TScan Therapeutics	0.00%	-3.34%	+1.41%	-25.40%	-58.14%
TIL Instil Bio	0.00%	0.00%	+6.46%	-6.54%	-71.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$9.85 -7.9%	$9.61	$3.02 ▼ $49.60	$19.21M	1.41	317,286 shs	56,721 shs
IMMP Prima BioMed	$0.37 -4.1%	$0.40	$0.29 ▼ $3.53	$53.86M	2.25	5.76 million shs	106,460 shs
TCRX TScan Therapeutics	$0.73 -3.8%	$0.87	$0.72 ▼ $2.57	$49.15M	1.06	670,385 shs	218,070 shs
TIL Instil Bio	$7.70 +1.6%	$7.48	$5.67 ▼ $33.83	$52.21M	1.94	55,466 shs	504 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+36.31%	+36.13%	-20.33%	-64.80%
IMMP Prima BioMed	0.00%	-1.32%	-0.26%	-4.18%	-76.34%
TCRX TScan Therapeutics	0.00%	-3.34%	+1.41%	-25.40%	-58.14%
TIL Instil Bio	0.00%	0.00%	+6.46%	-6.54%	-71.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	228.26% Upside
IMMP Prima BioMed	2.00	Hold	$5.50	1,404.79% Upside
TCRX TScan Therapeutics	2.43	Hold	$6.00	727.47% Upside
TIL Instil Bio	1.67	Reduce	$66.00	757.14% Upside

Current Analyst Ratings Breakdown

Latest AKTX, IMMP, TCRX, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	TCRX TScan Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/17/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$5.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
IMMP Prima BioMed	$6.69M	8.05	N/A	N/A	$0.63 per share	0.58
TCRX TScan Therapeutics	$7.11M	6.91	N/A	N/A	$2.16 per share	0.34
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	N/A
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)

Latest AKTX, IMMP, TCRX, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	H2 2026	IMMP Prima BioMed	-$0.0258	N/A	N/A	N/A	$11.73 million	N/A
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
IMMP Prima BioMed	N/A	2.97	N/A
TCRX TScan Therapeutics	0.31	3.37	3.37
TIL Instil Bio	0.79	21.67	21.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
IMMP Prima BioMed	2.32%
TCRX TScan Therapeutics	82.83%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
IMMP Prima BioMed	3.07%
TCRX TScan Therapeutics	6.25%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.95 million	1.32 million	Not Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
TCRX TScan Therapeutics	100	67.78 million	63.54 million	Not Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data

AKTX, IMMP, TCRX, and TIL Headlines

Recent News About These Companies

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26, 2026 | zacks.com

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, IMMP, TCRX, and TIL Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$9.85 -0.85 (-7.94%)

As of 12:27 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Prima BioMed NASDAQ:IMMP

$0.37 -0.02 (-4.07%)

As of 12:13 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

TScan Therapeutics NASDAQ:TCRX

$0.73 -0.03 (-3.77%)

As of 12:28 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Instil Bio NASDAQ:TIL

$7.70 +0.12 (+1.58%)

As of 11:19 AM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKTX, IMMP, TCRX, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKTX, IMMP, TCRX, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKTX, IMMP, TCRX, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, IMMP, TCRX, and TIL Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Prima BioMed NASDAQ:IMMP

TScan Therapeutics NASDAQ:TCRX

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKTX, IMMP, TCRX, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKTX, IMMP, TCRX, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKTX, IMMP, TCRX, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, IMMP, TCRX, and TIL Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Prima BioMed NASDAQ:IMMP

TScan Therapeutics NASDAQ:TCRX

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools